European Union Projects
CZ Vaccines has the support of the CDTI to carry out R&D projects that finance research of how MTBVAC stimulates specific immune responses that mimic natural tuberculosis infection without causing diseasegreater robustness to the generated data.
This project aims to expand the preclinical safety profile of MTBVAC by carrying out in vivo toxicology studies with the 5×106 CFU dose. Once this safety has been confirmed, the next step will be to manufacturer and validate a new clinical batch of MTBVAC 5×106 CFU, which will be released for its use in phase III clinical trials that are expected to begin in early 2022.
This project has been carried out at the company’s headquarters, in O Porriño, Galicia. Its execution schedule has been between July 2021 and August 2022. The project budget has been 314.381 €, and we have had the help of the CDTI and the Feder funds.